Cytokinetics, Inc. Stock Nasdaq
Equities
US23282W1009
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Apr. 26 | Cytokinetics Appoints Sung Lee as CFO | MT |
Apr. 26 | Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024 | CI |
Financials (USD)
Sales 2024 * | 12.06M | Sales 2025 * | 164M | Capitalization | 6.55B |
---|---|---|---|---|---|
Net income 2024 * | -466M | Net income 2025 * | -363M | EV / Sales 2024 * | 520 x |
Net cash position 2024 * | 276M | Net cash position 2025 * | 600M | EV / Sales 2025 * | 36.3 x |
P/E ratio 2024 * |
-14.2
x | P/E ratio 2025 * |
-19.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.42% |
Latest transcript on Cytokinetics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 60 | 98-06-30 |
Kari Loeser
CMP | Compliance Officer | - | 21-10-31 |
Stuart Kupfer
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy Wysenski
BRD | Director/Board Member | 66 | 20-11-19 |
Edward Kaye
BRD | Director/Board Member | 74 | 16-05-19 |
Santo Costa
BRD | Director/Board Member | 78 | 10-09-30 |
1st Jan change | Capi. | |
---|---|---|
-2.63% | 102B | |
+1.62% | 96.29B | |
+1.43% | 22.18B | |
-16.67% | 21.2B | |
-9.84% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |